Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Drug Dev Ind Pharm ; 45(10): 1635-1645, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31342792

RESUMEN

Objective: The aim of the study was to formulate, cyclodextrin (CD)-polyanhydride (PA) nanoparticles (CPNs) with rosuvastatin calcium (RCa) in order to enhance the poor oral bioavailability. Methods: CPNs containing RCa/CD complexes were prepared by a modified solvent displacement method and morphological analyses, particle size (PS), polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE), DSC, FT-IR, XRD, 1H-NMR analyses were performed. In vitro release properties, release kinetics, cytotoxicity, in vitro permeability and pharmacokinetic studies were also studied. The stability of the formulations were evaluated during the storage period of 3 months. Results: The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively. Sustained release of RCa from CPNs were achieved. The cytotoxicity values showed that the safety of the formulations. According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively. CPN2 formulation was selected for pharmacokinetic studies and analyses results demonstrated that approximately 8-fold relative oral bioavailability enhancement compared to the pure RCa was achieved. Conclusion: Considering the analyses results of the study, CPNs can be regarded as suitable, safe, functional oral delivery systems for RCa with enhanced oral bioavailability.


Asunto(s)
Ciclodextrinas/química , Ciclodextrinas/farmacocinética , Nanopartículas/química , Polianhídridos/química , Polianhídridos/farmacocinética , Rosuvastatina Cálcica/química , Rosuvastatina Cálcica/farmacocinética , Animales , Disponibilidad Biológica , Células CACO-2 , Línea Celular Tumoral , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/métodos , Humanos , Masculino , Tamaño de la Partícula , Permeabilidad/efectos de los fármacos , Ratas , Ratas Sprague-Dawley
2.
Biomacromolecules ; 16(5): 1650-9, 2015 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-25867183

RESUMEN

Surface eroding and semicrystalline polyanhydrides, with tunable erosion times and drug delivery pharmacokinetics largely dictated by erosion, are produced easily with thiol-ene "click" polymerization. This strategy yields both linear and cross-linked network polyanhydrides that are readily and fully cured within minutes using photoinitiation, can contain up to 60% crystallinity, and have tensile moduli up to 25 MPa for the compositions studied. Since they readily undergo hydrolysis and exhibit the oft-preferred surface erosion mechanism, they may be particularly useful in drug delivery applications. The polyanhydrides were degraded under pseudophysiological conditions and cylindrical samples (10 mm diameter × 5 mm height) were completely degraded within ∼10 days, with the mass-time profile being linear for much of this time after a ∼24 h induction period. Drug release studies, using lidocaine as a model, showed pharmacokinetics that displayed a muted burst release in the early stages of erosion, but then a delayed release profile that is closely correlated to the erosion kinetics. Furthermore, cytotoxicity studies of the linear and cross-linked semicrystalline polyanhydrides, and degradation products, against fibroblast cells indicate that the materials have good cytocompatibility. Overall, cells treated with up to 2500 mg/L of the semicrystalline polyanhydrides and degradation products show >90% human dermal fibroblast adult (HDFa) cell viability indicative of good cytocompatibility.


Asunto(s)
Sistemas de Liberación de Medicamentos , Polianhídridos/química , Polianhídridos/farmacología , Supervivencia Celular/efectos de los fármacos , Química Clic , Liberación de Fármacos , Fibroblastos/efectos de los fármacos , Humanos , Procesos Fotoquímicos , Polianhídridos/farmacocinética
3.
Biomed Microdevices ; 13(6): 1015-25, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21773725

RESUMEN

The aim was to study the ability of bioadhesive cyclodextrin-poly(anhydride) nanoparticles as carriers for the oral delivery of atovaquone (ATO). In order to increase the loading capacity of ATO by poly(anhydride) nanoparticles, the following oligosaccharides were assayed: 2-hydroxypropyl-ß-cyclodextrin (HPCD), 2,6-di-O-methyl-ß-cyclodextrin (DCMD), randomly methylated-ß-cyclodextrin (RMCD) and sulfobuthyl ether-ß-cyclodextrin (SBECD). Nanoparticles were obtained by desolvation after the incubation between the poly(anhydride) with the ATO-cyclodextrin complexes. For the pharmacokinetic studies, ATO formulations were administered orally in rats. Overall, ATO displayed a higher affinity for methylated cyclodextrins than for the other derivatives. However, for in vivo studies, both ATO-DMCD-NP and ATO-HPCD-NP were chosen. These nanoparticle formulations showed more adequate physicochemical properties in terms of size (<260 nm), drug loading (17.8 and 16.9 µg/mg, respectively) and yield (>75%). In vivo, nanoparticle formulations induced higher and more prolonged plasmatic levels of atovaquone than control suspensions of the drug in methylcellulose. Relative bioavailability of ATO when loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-DMCD NP), whereas for the suspension control formulation the bioavailability was only about 30%. The encapsulation of atovaquone in cyclodextrins-poly(anhydride) nanoparticles seems to be an interesting strategy to improve the oral bioavailability of this lipophilic drug.


Asunto(s)
Atovacuona/farmacología , Portadores de Fármacos/administración & dosificación , Nanopartículas/administración & dosificación , Polianhídridos/farmacocinética , beta-Ciclodextrinas/farmacocinética , 2-Hidroxipropil-beta-Ciclodextrina , Administración Oral , Animales , Disponibilidad Biológica , Fenómenos Químicos , Portadores de Fármacos/química , Diseño de Fármacos , Masculino , Nanopartículas/química , Ratas , Ratas Wistar , beta-Ciclodextrinas/administración & dosificación
4.
Eur J Pharm Sci ; 118: 165-175, 2018 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-29597043

RESUMEN

The aim of this work was to investigate the potential of pegylated poly(anhydride) nanoparticles to enhance the oral bioavailability of docetaxel (DTX). Nanoparticles were prepared after the incubation between the copolymer of methyl vinyl ether and maleic anhydride (Gantrez® AN), poly(ethylene glycol) (PEG2000 or PEG6000) and docetaxel (DTX). The oral administration of a single dose of pegylated nanoparticles to mice provided sustained and prolonged therapeutic plasma levels of docetaxel for up 48-72 h. In addition, the relative oral bioavailability of docetaxel was around 32%. The organ distribution studies revealed that docetaxel underwent a similar distribution when orally administered encapsulated in nanoparticles as when intravenously as Taxotere®. This observation, with the fact that the clearance of docetaxel when loaded into the oral pegylated nanoparticles was found to be similar to that of intravenous formulation, suggests that docetaxel would be released at the epithelium surface and then absorbed to the circulation.


Asunto(s)
Antineoplásicos/administración & dosificación , Portadores de Fármacos/administración & dosificación , Nanopartículas/administración & dosificación , Polianhídridos/administración & dosificación , Polietilenglicoles/administración & dosificación , Taxoides/administración & dosificación , Administración Oral , Animales , Antineoplásicos/sangre , Antineoplásicos/química , Antineoplásicos/farmacocinética , Disponibilidad Biológica , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Docetaxel , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Liberación de Fármacos , Femenino , Ratones Endogámicos BALB C , Nanopartículas/química , Polianhídridos/química , Polianhídridos/farmacocinética , Polietilenglicoles/química , Polietilenglicoles/farmacocinética , Taxoides/sangre , Taxoides/química , Taxoides/farmacocinética , Distribución Tisular
5.
Int J Pharm ; 334(1-2): 156-65, 2007 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-17118588

RESUMEN

Nanoparticles based on the poly(methyl vinyl ether-co-maleic anhydride) were pegylated with different types of PEGs, namely, two hydroxyl-functionalized PEGs (PEG and mPEG) and two amino-PEGs (DAE-PEG and DAP-PEG). The resulted nanoparticles demonstrated reduction of the negative surface charge compared to the non-modified particles. Further, in vivo experiments showed that all types of pegylated particles possessed higher affinity to adhere to intestinal rather than to the stomach mucosa. Higher bioadhesive potential was observed in the case of PEG-NP and DAE-PEG-NP which was attributed to the flexibility and specific properties of the surface "brush" layer of these particles. The lower bioadhesive potential of mPEG-NP was due to the low presence of coating "brush" layer, whereas for DAP-PEG-NP to the fact that the double end coupled chains ("loop"-conformation) were not available for intensive interactions with the mucosa. The observations made by optic microscopy illustrated an intracellular transport of PEG-NP in vivo with preferable location in the apical area of enterocytes.


Asunto(s)
Portadores de Fármacos , Nanopartículas/química , Polianhídridos/farmacocinética , Polietilenglicoles/farmacocinética , Polímeros/química , Adhesividad , Administración Oral , Animales , Transporte Biológico , Preparaciones de Acción Retardada/síntesis química , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Sistemas de Liberación de Medicamentos , Enterocitos/metabolismo , Mucosa Gástrica/citología , Mucosa Gástrica/metabolismo , Absorción Intestinal , Mucosa Intestinal/citología , Mucosa Intestinal/metabolismo , Tamaño de la Partícula , Polianhídridos/síntesis química , Polianhídridos/química , Polietilenglicoles/síntesis química , Polietilenglicoles/química , Ratas , Ratas Wistar , Propiedades de Superficie
6.
J Biomed Mater Res A ; 76(1): 102-10, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16138330

RESUMEN

We have designed a new synthesis route to create polyanhydrides based on monomers that contain hydrophilic entities within highly hydrophobic backbones. The method results in polyanhydrides that can be easily processed into drug-containing tablets. The synthesis, characterization, and erosion studies of polyanhydride copolymers based on 1,6-bis(p-carboxyphenoxy)hexane (CPH), which is highly hydrophobic, and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), which has hydrophilic oligomeric ethylene glycol segments in the monomer unit, was performed using a combination of molecular spectroscopy, thermal analysis, gravimetry, and scanning electron microscopy. The studies demonstrate that by increasing the CPH content in the CPTEG:CPH copolymers, the erosion of the system can be tailored from bulk-eroding to surface-eroding mechanism. These systems have promise as protein carriers.


Asunto(s)
Materiales Biocompatibles/síntesis química , Polianhídridos/síntesis química , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacocinética , Biodegradación Ambiental , Portadores de Fármacos , Espectroscopía de Resonancia Magnética , Ensayo de Materiales , Microscopía Electrónica de Rastreo , Polianhídridos/química , Polianhídridos/farmacocinética , Solubilidad , Propiedades de Superficie , Termodinámica
7.
J Biomed Nanotechnol ; 12(7): 1544-52, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-29337493

RESUMEN

Polyanhydride nanoparticles have emerged as a versatile delivery platform, due to their ability to encapsulate diverse drugs, immunogens, antibodies, and proteins. However, mechanistic studies on the effects of particle chemistry interactions with immune cells have yet to be described. Understanding the mechanism by which these particles are internalized by immune cells will enable rational selection of delivery vehicles for specific applications. In the present study, the internalization, mechanism(s) of uptake by monocytes, and intracellular fate of polyanhydride nanoparticles were evaluated using copolymers based on 1,6-bis(p-carboxyphenoxy)hexane (CPH), sebacic acid (SA), and 1,8-bis(p-carboxyphenoxy)3,6-dioxaoctane (CPTEG). The results showed that 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles were internalized to a greater extent by monocytes as compared to the 50:50 CPH:SA and 50:50 CPTEH:CPH nanoparticles. Further, cytochalasin-D treatment of cells inhibited uptake of all the particles, regardless of chemistry, indicating that actinmediated uptake is the primary mechanism of cellular entry for these particles. The insights gained from these studies were used to identify lead nanoparticle formulations to enhance treatment of intracellular bacterial infections. The use of doxycycline-loaded nanoparticles exhibited enhanced therapeutic efficacy compared to soluble drug in treating monocyte monolayers infected with the virulent intracellular pathogen Brucella abortus. Altogether, these studies demonstrate how rational design and selection of nanoscale delivery platforms can be used for a wide spectrum of biomedical applications.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Monocitos/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Polianhídridos/farmacocinética , Polietilenglicoles/farmacocinética , Animales , Antibacterianos/química , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Brucella/efectos de los fármacos , Línea Celular , Ácidos Decanoicos/química , Ácidos Decanoicos/farmacocinética , Ácidos Dicarboxílicos/química , Ácidos Dicarboxílicos/farmacocinética , Doxiciclina/química , Doxiciclina/farmacocinética , Doxiciclina/farmacología , Hexanos/química , Hexanos/farmacocinética , Humanos , Ratones , Monocitos/microbiología , Polianhídridos/química , Polietilenglicoles/química , Células RAW 264.7
8.
J Drug Target ; 13(4): 225-33, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-16051534

RESUMEN

New microparticles containing amphotericin B (AMB) have been developed and manufactured by spray drying. To this end albumin, polylactic-co-glycolic acids (PLGA) and poly(sebacic anhydride) have been employed as drug carriers. The selection of the solvent used to disperse the drug and the vehicle before spray drying was critical on production yields and physical properties of the microparticles. Once particle size, morphology and dispersability in some aqueous media were shown to be acceptable for an intravenous administration, in vivo efficacy was evaluated and compared with the reference medicine Fungizone. Microparticles prepared with albumin, albumin heated at a high temperature, some kinds of PLGA or polyanhydride, as well as Fungizone, were tested in an experimental hamster model of infection with Leishmania infantum, by evaluating the evolution of parasitic burdens in spleen, liver and antibody responses. After the injection of three doses corresponding to 2 mg of AMB per kilogram each, diverse reactions were reported depending on the vehicle. The best dispersability, reduction of parasites and antibody response were achieved when the treatment was performed with AMB in albumin microspheres.


Asunto(s)
Anfotericina B/farmacocinética , Antiprotozoarios/farmacocinética , Portadores de Fármacos/farmacocinética , Leishmaniasis Visceral/tratamiento farmacológico , Hígado/metabolismo , Bazo/metabolismo , Albúminas/farmacocinética , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Animales , Antígenos de Protozoos/análisis , Antiprotozoarios/administración & dosificación , Antiprotozoarios/uso terapéutico , Cricetinae , Composición de Medicamentos , Ácido Láctico/farmacocinética , Leishmania infantum/efectos de los fármacos , Leishmaniasis Visceral/metabolismo , Hígado/parasitología , Masculino , Mesocricetus , Microesferas , Tamaño de la Partícula , Polianhídridos/farmacocinética , Ácido Poliglicólico/farmacocinética , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/farmacocinética , Bazo/parasitología
9.
Drug Deliv ; 12(2): 97-102, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15824034

RESUMEN

Poly [bi(o-carboxyphenyl)adipate-polyethylene glycol] anhydrides--P(BOCA-PEG)--polymeric drugs were synthesized and characterized by Fourier transformed infrared spectroscopy, NMR, DSC, gel permeation chromatography, etc. Salicylic acid loading efficiency of these polymers ranged from 43.5% to 71.3%, which was much higher than that of other polymeric drugs with salicylic acid. The in vitro release of salicylic acid from the polymers was carried out in buffer conditions with different pH values and and rat gastrointestinal contents. The results showed the release rate of salicylic acid increased with the increase of PEG content in the polymers and the increase of pH value of degradation buffer solution. The rat cecal contents also greatly promoted the release of salicylic acid. In 0.1M phosphate buffer solution at pH8.0, 37 degrees C containing 5% rat cecal contents, P(BOCA-PEG200)(80:20) had 15% salicylic acid released in 21 hr, indicating its potential use in colon-specific salicylic acid delivery.


Asunto(s)
Polianhídridos/síntesis química , Polietilenglicoles/síntesis química , Ácido Salicílico/síntesis química , Animales , Polianhídridos/farmacocinética , Polietilenglicoles/farmacocinética , Ratas , Ratas Sprague-Dawley , Ácido Salicílico/farmacocinética
10.
Nanoscale ; 6(22): 13770-8, 2014 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-25285425

RESUMEN

Acute respiratory infections represent a significant portion of global morbidity and mortality annually. There is a critical need for efficacious vaccines against respiratory pathogens. To vaccinate against respiratory disease, pulmonary delivery is an attractive route because it mimics the route of natural infection and can confer both mucosal and systemic immunity. We have previously demonstrated that a single dose, intranasal vaccine based on polyanhydride nanoparticles elicited a protective immune response against Yersinia pestis for at least 40 weeks after immunization with F1-V. Herein, we investigate the effect of nanoparticle chemistry and its attributes on the kinetics and maturation of the antigen-specific serum antibody response. We demonstrate that manipulation of polyanhydride nanoparticle chemistry facilitated differential kinetics of development of antibody titers, avidity, and epitope specificity. The results provide new insights into the underlying role(s) of nanoparticle chemistry in providing long-lived humoral immunity and aid in the rational design of nanovaccine formulations to induce long-lasting and mature antibody responses.


Asunto(s)
Formación de Anticuerpos/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/química , Nanomedicina Teranóstica , Yersinia pestis/inmunología , Administración Intranasal , Animales , Disponibilidad Biológica , Inmunización/métodos , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/metabolismo , Ratones , Ratones Endogámicos C57BL , Peste/metabolismo , Peste/prevención & control , Vacuna contra la Peste/síntesis química , Vacuna contra la Peste/farmacocinética , Polianhídridos/síntesis química , Polianhídridos/química , Polianhídridos/farmacocinética
11.
Int J Nanomedicine ; 8: 2213-25, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23818778

RESUMEN

Several challenges are associated with current vaccine strategies, including repeated immunizations, poor patient compliance, and limited approved routes for delivery, which may hinder induction of protective immunity. Thus, there is a need for new vaccine adjuvants capable of multi-route administration and prolonged antigen release at the site of administration by providing a depot within tissue. In this work, we designed a combinatorial platform to investigate the in vivo distribution, depot effect, and localized persistence of polyanhydride nanoparticles as a function of nanoparticle chemistry and administration route. Our observations indicated that the route of administration differentially affected tissue residence times. All nanoparticles rapidly dispersed when delivered intranasally but provided a depot when administered parenterally. When amphiphilic and hydrophobic nanoparticles were administered intranasally, they persisted within lung tissue. These results provide insights into the chemistry- and route-dependent distribution and tissue-specific association of polyanhydride nanoparticle-based vaccine adjuvants.


Asunto(s)
Adyuvantes Inmunológicos/farmacocinética , Preparaciones de Acción Retardada/farmacocinética , Nanopartículas/metabolismo , Polianhídridos/farmacocinética , Vacunas , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/química , Administración Intranasal , Análisis de Varianza , Animales , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Sistemas de Liberación de Medicamentos , Colorantes Fluorescentes/química , Inyecciones Intramusculares , Pulmón/química , Ratones , Nanopartículas/administración & dosificación , Nanopartículas/química , Polianhídridos/administración & dosificación , Polianhídridos/química , Distribución Tisular , Imagen de Cuerpo Entero
12.
Expert Opin Drug Deliv ; 8(6): 721-34, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21463219

RESUMEN

INTRODUCTION: The oral administration of drugs belonging to Class IV of the Biopharmaceutical Classification System (BCS) represents a major challenge. These drugs display poor aqueous solubility and specific permeability characteristics. Most of these compounds are substrates of the P-glycoprotein and/or the cytochrome P450. Among other types of drug, various anti-cancer drugs also suffer from these drawbacks (i.e., paclitaxel), which limits the possibilities for developing oral treatments. AREAS COVERED: This review discusses the factors that influence the bioavailability of drugs when administered by the oral route, as well as the capabilities of cyclodextrins when associated with nanoparticles. In particular, evidence is given regarding the synergistic effect between cyclodextrins and bioadhesive nanoparticles, on the oral delivery of pharmaceuticals. EXPERT OPINION: This article aims to provide an overview of the multiple gains in incorporating cyclodextrins in poly(anhydride) nanoparticles, including improvement of their bioadhesive capability, the loading of lipophilic drugs and the effect on efflux membrane proteins and cytochrome P450. The combination between bioadhesive nanoparticles and P-gp inhibitors without pharmacological activity (i.e., cyclodextrins) may be useful to promote the oral bioavailability of drugs ascribed to Class IV of the BCS.


Asunto(s)
Ciclodextrinas/química , Portadores de Fármacos/química , Nanopartículas/química , Polianhídridos/química , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Absorción , Administración Oral , Animales , Disponibilidad Biológica , Ciclodextrinas/farmacocinética , Ciclodextrinas/farmacología , Inhibidores Enzimáticos del Citocromo P-450 , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/farmacología , Humanos , Paclitaxel/administración & dosificación , Paclitaxel/química , Paclitaxel/farmacocinética , Polianhídridos/farmacocinética , Polianhídridos/farmacología , Solubilidad , Propiedades de Superficie , Distribución Tisular
13.
Eur J Pharm Sci ; 38(4): 405-13, 2009 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-19765652

RESUMEN

The aim of this work was to study the effect of the combination between 2-hydroxypropyl-beta-cyclodextrin (HPCD) and bioadhesive nanoparticles on the encapsulation and intestinal permeability of paclitaxel (PTX). In this context, a solid inclusion complex between PTX and HPCD was prepared by an evaporation method. Then, the complex was incorporated in poly(anhydride) nanoparticles by a solvent displacement method. The resulting nanoparticles, PTX-HPCD NP, displayed a size of about 300 nm and a drug loading of about 170 microg/mg (500-fold higher than in the absence of HPCD). The effect of these nanoparticles on the permeability of intestinal epithelium was investigated using the Ussing chamber technique. The apparent permeability (P(app)) of PTX was found to be 12-fold higher when formulated as PTX-HPCD NP than when formulated as Taxol (control). Furthermore, when interaction between nanoparticles and the mucosa was avoided, the permeability of PTX significantly decreased. In summary, the association between PTX-HPCD and poly(anhydride) nanoparticles would induce a positive effect over the intestinal permeability of paclitaxel, being the bioadhesion a mandatory condition in this phenomena.


Asunto(s)
Nanopartículas , Paclitaxel/farmacocinética , Polianhídridos/farmacocinética , beta-Ciclodextrinas/farmacocinética , 2-Hidroxipropil-beta-Ciclodextrina , Administración Oral , Animales , Combinación de Medicamentos , Sinergismo Farmacológico , Absorción Intestinal/efectos de los fármacos , Absorción Intestinal/fisiología , Yeyuno/efectos de los fármacos , Yeyuno/metabolismo , Masculino , Nanopartículas/administración & dosificación , Paclitaxel/administración & dosificación , Permeabilidad/efectos de los fármacos , Polianhídridos/administración & dosificación , Ratas , Ratas Wistar , beta-Ciclodextrinas/administración & dosificación
14.
Pharm Res ; 26(3): 683-90, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18987960

RESUMEN

PURPOSE: To demonstrate that polyanhydride copolymer chemistry affects the uptake and intracellular compartmentalization of nanospheres by THP-1 human monocytic cells. METHODS: Polyanhydride nanospheres were prepared by an anti-solvent nanoprecipitation technique. Morphology and particle diameter were confirmed via scanning election microscopy and quasi-elastic light scattering, respectively. The effects of varying polymer chemistry on nanosphere and fluorescently labeled protein uptake by THP-1 cells were monitored by laser scanning confocal microscopy. RESULTS: Polyanhydride nanoparticles composed of poly(sebacic anhydride) (SA), and 20:80 and 50:50 copolymers of 1,6-bis-(p-carboxyphenoxy)hexane (CPH) anhydride and SA were fabricated with similar spherical morphology and particle diameter (200 to 800 nm). Exposure of the nanospheres to THP-1 monocytes showed that poly(SA) and 20:80 CPH:SA nanospheres were readily internalized whereas 50:50 CPH:SA nanospheres had limited uptake. The chemistries also differentially enhanced the uptake of a red fluorescent protein-labeled antigen. CONCLUSIONS: Nanosphere and antigen uptake by monocytes can be directly correlated to the chemistry of the nanosphere. These results demonstrate the importance of choosing polyanhydride chemistries that facilitate enhanced interactions with antigen presenting cells that are necessary in the initiation of efficacious immune responses.


Asunto(s)
Ácidos Decanoicos/química , Portadores de Fármacos/química , Monocitos/metabolismo , Nanosferas/química , Polianhídridos/química , Poliésteres/química , Células Presentadoras de Antígenos , Antígenos de Superficie/administración & dosificación , Línea Celular , Precipitación Química , Ácidos Decanoicos/síntesis química , Ácidos Decanoicos/farmacocinética , Ácidos Dicarboxílicos/química , Portadores de Fármacos/síntesis química , Portadores de Fármacos/farmacocinética , Hexanos/química , Humanos , Microscopía Confocal , Microscopía Electrónica de Rastreo , Tamaño de la Partícula , Polianhídridos/síntesis química , Polianhídridos/farmacocinética , Poliésteres/síntesis química , Poliésteres/farmacocinética , Propiedades de Superficie , Vacunas/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA